Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Jun;47(6):645-650. Korean.
    Published online Jun 30, 2006.
    https://doi.org/10.4111/kju.2006.47.6.645
    Copyright © 2006 The Korean Urological Association
    Original Article

    Therapeutic Efficacy of Extracorporeal Magnetic Therapy on Low Urinary Tract Symptoms and Sexual Function in Chronic Pelvic Pain Syndrome

    Hang Ro Park, Seung Gun Gho and Hyoung Jin Kim
      • Department of Urology, Sung Ae General Hospital, Seoul, Korea.
    • Corresponding author (Email: urokhj@dreamwiz.com )
    Received January 04, 2006; Accepted May 10, 2006.

    Abstract

    Purpose

    To find whether extracorporeal magnetic innervation (ExMi) changes the low urinary tract symptoms and sexual function in patients with chronic pelvic pain syndrome (CPPS).

    Materials and Methods

    ExMi treatment was performed in 51 patients, diagnosed as National Institute of Health (NIH) type III prostatitis, with each treatment session composed of 10 min at 40Hz, 2 min rest and 10 min at 50Hz. Both before and after the completion of 8 sessions of ExMi, self-administered NIH-chronic prostatitis symptom index (NIH-CPSI) and International Index of Erectile Function (IIEF) questionnaires were completed to assess the changes in the patient's symptoms.

    Results

    Following the ExMi treatment, 25 of the 40 patients experienced a 30% or greater improvement of low urinary tract symptoms. The total NIH-CPSI scores ranged from 22.4 to 15.6 (p<0.05). Each domain of the NIH-CPSI was as follows: pain, from 9.0 to 6.2; urination, from 6.7 to 4.8 and effect on the quality of life, from 6.6 to 4.5, and 11 of the 26 patients experienced a 15% or greater improvement of their sexual function. The mean total IIEF scores ranged from 44.1±13.5 to 51.6±11.3 (p<0.05). Each domain of the IIEF was as follows: erectile function, from 19.5±7.0 to 21.7±5.6 (p<0.05); intercourse satisfaction, from 7.4±2.2 to 9.5±2.2 (p<0.05); orgasm function, from 6.5±2.2 to 6.6±2.6 (p=0.516); sexual desire, from 6.2±1.9 to 6.3±1.6 (p=0.294) and overall satisfaction from 5.4±1.5 to 7.3±1.3 (p<0.05).

    Conclusions

    From the result, ExMi was shown to reduce the lower urinary tract symptoms, and enhances the sexual function in CPPS, suggesting ExMi is effective and may help in the management of CPPS.

    Keywords
    Pelvic pain; Magnetics

    Figures

    Fig. 1
    The NIH-CPSI scores before and after 8 sessions of ExMi treatment in CPPS patients. The total NIH-CPSI scores and all domains of the NIH-CPSI show statistically significant differences. NIH-CPSI: National Institute of Health-chronic prostatitis symptom index, ExMi: extracorporeal magnetic innervation, CPPS: chronic pelvic pain syndrome. QoL: quality of life.

    Fig. 2
    NIH-CPSI scores before and after 8 sessions of ExMi treatment in CPPS patients above and below 50 years of age. There are no differences between the two age groups in relation to ExMi efficacy: p=0.659. NIH-CPSI: National Institute of Health-chronic prostatitis symptom index, ExMi: extracorporeal magnetic innervation, CPPS: chronic pelvic pain syndrome.

    Fig. 3
    IIEF scores before and after 8 sessions of ExMi treatment in CPPS patients. The total IIEF score and those for the erectile function, intercourse satisfaction and overall satisfaction in domains of the IIEF all show statistically significant differences. IIEF: International Index of Erectile Function, ExMi: extracorporeal magnetic innervation, CPPS: chronic pelvic pain syndrome.

    Fig. 4
    IIEF scores before and after 8 sessions of ExMi treatment in CPPS patients above and below 50 years of age. There are no differences between the two groups in relation to ExMi efficacy: p=0.234. IIEF: International Index of Erectile Function, ExMi: extracorporeal magnetic innervation, CPPS: chronic pelvic pain syndrome.

    Tables

    Table 1
    The results of the ExMi treatment according to the NIH-CPSI improvement scale

    Table 2
    The results of the ExMi treatment according to the IIEF improvement scale

    References

      1. Collins MM, Stafford RS, O'Leary P, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1997;157 Suppl:243A.
        abstract 950.
      1. Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 1996;155:965–968.
      1. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236–237.
      1. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999;54:229–233.
      1. Lee KS, Yoon JM, Cho IR. NIH-chronic prostatitis symptom index (NIH-CPSI). Prostate update 5 year 2002;1:108–121.
      1. Oh SH, Oh BR, Ryu SB. Effect of finasteride on sexual function in patients with benign prostatic hyperplasia. Korean J Urol 2002;43:611–618.
      1. Brahler E. Complaint complexes and psychosomatic aspects. In: Weidner W, Madsen PO, Schiefer HG, editors. Prostatitis etipathology, diagnosis and treatment. 1st ed. Berlin: Springer-Verlag; 1994. pp. 40-48.
      1. Krieger JN, Egan KJ, Ross SO, Jacobs R, Berger RE. Chronic pelvic pains represent the most prominant urogenital symptoms of "chronic prostatitis". Urology 1996;48:715–722.
      1. Cho IR, Park SC, Park SS. The prevalence of the symptoms of the prostate syndrome patients under 50. Korean J Urol 1998;39:751–756.
      1. Krieger JN, Ross SO, Riley DE. Chronic prostatitis; epidemiology and role of infection. Urology 2002;60 6 Suppl:8–12.
      1. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:839–845.
      1. El-Hakim A, Shah DK, Smith AD. Advanced therapy for prostatitis: minimally invasive and invasive therapies. Curr Urol Rep 2003;4:320–326.
      1. Zvara P, Folsom JB, Plante MK. Minimally invasive therapies for prostatitis. Curr Urol Rep 2004;5:320–326.
      1. Yamanishi T, Yasuda K, Suda S, Ishikawa N. Effect of functional continuous magnetic stimulation on urethral closure in healthy volunteers. Urology 1999;54:652–655.
      1. Hallett M, Cohen LG. Magnetism. A new method for stimulation of nerve and brain. JAMA 1989;262:538–541.
      1. Roth BJ, Cohen LG, Hallett M. The electric field induced during magnetic stimulation. Electroencephalogr Clin Neurophysiol 1991;43 Suppl:268–278.
      1. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;150:971–979.
      1. Guskov AR, Vasiliev AI. An electrostimulator to restore sexual function in chronic prostatitis patients. Med Prog Technol 1992;18:43–46.
      1. Kim SW, Kim SH, Lee CH, Lee SJ, Cho YH, Yoon MS. Clinical efficacy of extracorporeal magnetic innervation for chronic pelvic pain syndrome. Korean J Androl 2003;21:44–47.
      1. Lee KC, Choi H, Park HS, Kim JJ, Moon DG. Therapeutic efficacy of extracorporeal magnetic therapy in chronic pelvic pain syndrome. Korean J Urol 2003;44:693–696.
      1. Leippold T, Strebel RT, Huwyler M, John HA, Hauri D, Schmid DM. Sacral magnetic stimulation in non-inflammatory chronic pelvic pain syndrome. BJU Int 2005;95:838–841.
      1. Galloway NT, El-Galley RE, Sand PK, Appell RA, Russell HW, Carlan SJ. Extracorporeal magnetic innervation therapy for stress urinary incontinence. Urology 1999;53:1108–1111.
      1. Kim KH, Hong JY, Yoon HN. Early experience with extracorporeal magnetic innervation (ExMI) therapy for stress urinary incontinence. Korean J Urol 2001;42:938–941.
    MeSH Terms
    Humans
    Lower Urinary Tract Symptoms
    Orgasm
    Pelvic Pain*
    Prostatitis
    Quality of Life
    Surveys and Questionnaires
    Urinary Tract*
    Urination
    Metrics
    Share
    Figures
    slide
    slide
    slide
    slide

    1 / 4

    Tables
    slide
    slide

    1 / 2

    PERMALINK